The Risks of Adopting Foreign Price Controls for Drugs
Recent reports indicate that President Donald Trump is urging House Republicans to adopt a “most favored nation” (MFN) policy for Medicaid drug purchasing, linking U.S. prices to the lowest rates paid by other countries. While the goal of reducing Medicaid costs is understandable—particularly amid growing concerns about drug affordability—relying on foreign pricing benchmarks would risk importing the very market distortions that have constrained innovation abroad.
U.S. drug policy must navigate a careful balance: ensuring access and affordability for patients, without undermining the revenue streams that fund medical breakthroughs. Rather than mirroring international price controls—which would only lead to shortages in the long term—policymakers should explore trade-based strategies to address foreign-pricing practices that shift the global burden of pharmaceutical research and development disproportionately onto American consumers, thereby driving up costs for American consumers.